Vaxart, Inc.

107 articles about Vaxart, Inc.

• Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

  11/2/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the third quarter of 2023.

• Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

  11/2/2023

  Vaxart, Inc. announced it has dosed the first subject in its Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers.

• Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

  10/26/2023

  Vaxart, Inc. announced it will provide a business update and report financial results for the third quarter ended September 30, 2023 after the market close on Thursday, November 2, 2023.

• Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

  10/11/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023.

• Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

  9/21/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference in New York on Thursday, September 28, 2023 at 2:25 p.m. ET.

• Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

  9/6/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced top-line data from the Phase 2 challenge study of its oral tablet monovalent norovirus vaccine candidate (NCT05212168).

• Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

  8/3/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the second quarter of 2023.

• Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

  7/27/2023

  Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2023 after the market close on Thursday, August 3, 2023.

• Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

  7/6/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate.

• Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

  6/26/2023

  Vaxart, Inc. held its Annual Meeting of Shareholders in a virtual-only format.

• Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

  6/21/2023

  Vaxart, Inc. encourages its stockholders of record on April 28, 2023, to vote on its proxy if they have not yet done so.

• Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

  6/7/2023

  Vaxart, Inc. announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock, for gross proceeds of approximately $15,000,000, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Vaxart.

• Vaxart, Inc. Announces Proposed Public Offering of Common Stock - June 06, 2023

  6/6/2023

  Vaxart, Inc. announced that it has commenced an underwritten public offering of its common stock.

• Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate

  6/6/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced that the last subject has completed dosing in the Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate.

• Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results  

  5/4/2023

  Vaxart, Inc. announced its business update and financial results for the first quarter of 2023.

• Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4

  4/28/2023

  Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 4, 2023.

• Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6

  3/29/2023

  Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will make presentations at the World Vaccine Congress Washington 2023 in Washington, D.C. on Wednesday, April 5 and Thursday, April 6, 2023.

• Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

  3/17/2023

  Vaxart, Inc. (NASDAQ: VXRT) today announced it will host a key opinion leader video webcast on the health and economic impact and disease burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET.

• Vaxart Provides Business Update and Full Year 2022 Financial Results

  3/15/2023

  Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the full year 2022, during which Vaxart announced it is prioritizing development of the Company’s bivalent norovirus candidate.

• Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

  3/8/2023

  Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2022 after the market close on Wednesday, March 15, 2023.